Xianruida Medical-B (06669) announced 2023 annual results. Profit attributable to shareholders of 144.87 million yuan decreased by 79.35% year-on-year

According to the Zhitong Finance App, Xianruida Medical-B (06669) announced annual results for the year ended December 31, 2023. The group achieved revenue of 474 million yuan (RMB, same below) during the period, an increase of 19.8%; profit attributable to the company's equity shareholders was 14.487 million yuan, a year-on-year decrease of 79.35%; and basic profit per share was 0.05 yuan.

According to the announcement, the stable and favorable state of production and research has directly led to a rapid increase in annual earnings. During the reporting period, the Group's revenue was approximately $474 million, an increase of approximately 19.8% over the previous year. The Group's core products, ACoArt Orchid® & Dhalia® and ACoArt Tulip® & Litos®, became the Group's core revenue sources.